$-0.47
(Market cap
$33 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.4
-
Face value
--
-
Shares outstanding
25,499,155
10 Years Aggregate
CFO
$-68.29 Mln
EBITDA
$-79.02 Mln
Net Profit
$-93.14 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
NanoViricides (NNVC)
| 4.0 | -- | -28.4 | -15.5 | -6.8 | -21.4 | -27.9 |
|
BSE Sensex
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
NanoViricides (NNVC)
| -21.0 | 39.8 | -8.1 | -70.2 | 29.6 | 14.3 | -37.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
NanoViricides (NNVC)
|
1.2 | 33.4 | 0.0 | -8.1 | -- | -99.1 | -- | 3.7 |
| 83.3 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 264.1 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 70.6 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 58.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 109.0 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 367.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 541.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.8 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 352.6 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout NanoViricides (NNVC)
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications... and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut. Read more
-
Executive Chairman, President, CEO & Secretary
Dr. Anil R. Diwan Ph.D.
-
Executive Chairman, President, CEO & Secretary
Dr. Anil R. Diwan Ph.D.
-
Headquarters
Shelton, CT
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for NanoViricides (NNVC)
What is the current share price of NanoViricides Inc (NNVC) Today?
The share price of NanoViricides Inc (NNVC) is $1.18 (NYSE) as of 02-Sep-2026 12:37 EDT. NanoViricides Inc (NNVC) has given a return of -6.77% in the last 3 years.
What is the current PB & PE ratio of NanoViricides Inc (NNVC)?
Since, TTM earnings of NanoViricides Inc (NNVC) is negative, P/E ratio is not available.
The P/B ratio of NanoViricides Inc (NNVC) is 3.73 times as on 21-Aug-2026, a 28 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-2.44 |
3.07 |
2024 |
-2.46 |
1.78 |
2023 |
-1.57 |
0.90 |
2022 |
-2.69 |
0.94 |
2021 |
-6.06 |
1.79 |
What is the 52 Week High and Low of NanoViricides Inc (NNVC)?
The 52-week high and low of NanoViricides Inc (NNVC) are Rs 2.23 and Rs 0.85 as of 02-Sep-2026.
What is the market cap of NanoViricides Inc (NNVC)?
NanoViricides Inc (NNVC) has a market capitalisation of $ 33 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in NanoViricides Inc (NNVC)?
Before investing in NanoViricides Inc (NNVC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.